Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy - Darb-Esfahani, Silvia; Stenzinger, Albrecht; Endris, Volker; Sinn, Peter (OncoTarget, 2016)
Gesehen am 03.11.2017